目的 分析2型糖尿病患者通过达格列净联合二甲双胍治疗的临床效果.方法 60例2型糖尿病患者,通过随机数字表法分为对照组、观察组,各30例.对照组给予二甲双胍治疗,观察组在对照组基础上加用达格列净治疗.对比两组患者血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]检测结果、临床疗效、血脂指标[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)]及胰岛功能指标[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛 β 细胞功能指数(HOMA-β)].结果 施治后,观察组FPG(5.26±0.15)mmol/L、2 h PG(9.59±1.07)mmol/L、HbA1c(6.26±0.35)%均低于对照组的(6.63±0.27)mmol/L、(11.16±1.30)mmol/L、(7.95±0.26)%(P<0.05).观察组治疗总有效率达96.67%,高于对照组的80.00%(P<0.05).施治后,观察组LDL-C(2.32±0.16)mmol/L、TC(3.26±0.15)mmol/L、TG(1.62±0.15)mmol/L低于对照组的(3.05±0.27)、(4.16±0.30)、(2.03±0.20)mmol/L,HDL-C(1.41±0.20)mmol/L高于对照组的(1.20±0.13)mmol/L(P<0.05).施治后,观察组FINS(10.26±1.03)μIU/L、HOMA-β(70.85±5.97)% 高于对照组的(8.85±1.07)μIU/L、(65.33±7.08)%,HOMA-IR(2.03±0.13)低于对照组的(2.63±0.25)(P<0.05).结论 2型糖尿病患者采用达格列净联合二甲双胍治疗可有效改善患者的血糖水平及胰岛功能,提升治疗效果并有效调节糖脂代谢.
Observation on the effect of dapaglipzin combined with metformin in the treatment of type 2 diabetes mellitus
Objective To analyze the clinical effect of dapaglipzin combined with metformin in the treatment of type 2 diabetes mellitus. Methods 60 patients with type 2 diabetes mellitus were divided into a control group and an observation group by random number table method,with 30 cases in each group. The control group was treated with metformin,and the observation group was treated with dapaglipzin on the basis of the control group. Patients in both groups were compared in terms of fasting plasma glucose (FPG),2 h postprandial glucose (2 h PG),glycated hemoglobin (HbA1c)]test results,clinical efficacy,blood lipid indicators[high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C),total cholesterol (TC),triglyceride (TG)]and islet function indicators[fasting insulin (FINS),homeostasis assessment model of insulin resistance (HOMA-IR),homeostasis assessment model of β-cell function (HOMA-β)]. Results After treatment,the observation group had FPG of (5.26±0.15) mmol/L,2 h PG of (9.59±1.07) mmol/L and HbA1c of (6.26±0.35)%,which were lower than (6.63±0.27) mmol/L,(11.16±1.30) mmol/L and (7.95±0.26)% in the control group (P<0.05). The total effective rate of the observation group was 96.67%,which was higher than 80.00% of the control group (P<0.05). After treatment,the observation group had LDL-C of (2.32±0.16) mmol/L,TC of (3.26±0.15) mmol/L and TG of (1.62±0.15) mmol/L,which were lower than (3.05±0.27),(4.16±0.30) and (2.03±0.20) mmol/L in the control group;the observation group had higher HDL-C of (1.41±0.20) mmol/L than (1.20±0.13) mmol/L in the control group (P<0.05). After treatment,the observation group had FINS of (10.26±1.03) μIU/L and HOMA-β of (70.85±5.97)%,which were higher than (8.85±1.07) μIU/L and (65.33±7.08)% in the control group;the observation group had lower HOMA-IR of (2.03±0.13) than (2.63±0.25) in the control group (P<0.05). Conclusion Dapaglipzin combined with metformin can effectively improve the blood glucose level and islet function,enhance the therapeutic effect and effectively regulate glucose and lipid metabolism in patients with type 2 diabetes.
Type 2 diabetes mellitusDapaglipzinMetforminBlood glucose